Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "appointment"

284 News Found

Dr. B.N. Gangadhar appointed as Chairperson of the National Medical Commission
People | July 04, 2024

Dr. B.N. Gangadhar appointed as Chairperson of the National Medical Commission

Dr. Sanjay Behari, Director of Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, as the President of the Medical Assessment and Rating Board


Avallano appoints Michael A. Ibara as Chief Strategy Officer
News | July 03, 2024

Avallano appoints Michael A. Ibara as Chief Strategy Officer

Ibara will drive AI-powered clinical research innovation


Sanofi Consumer Healthcare India appoints Himanshu Bakshi as MD
Appointment | June 27, 2024

Sanofi Consumer Healthcare India appoints Himanshu Bakshi as MD

Himanshu brings with him a wealth of rich experience from commercial, marketing, and general management roles


AbbVie appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
People | June 22, 2024

AbbVie appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors

Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director


Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
People | June 17, 2024

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,


AxoSim appoints Alif Saleh as CEO
People | June 14, 2024

AxoSim appoints Alif Saleh as CEO

Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer


Takeda appoints Annapurna Das as the General Manager, India Operations
People | May 17, 2024

Takeda appoints Annapurna Das as the General Manager, India Operations

Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines


Lonza reports softer performance in Q1 2024
News | May 14, 2024

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s